| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| 25mg | |||
| 50mg | |||
| Other Sizes |
| Targets |
X-ray contrast activity. Iotalamic acid is a radiographic contrast agent that works through its iodine content to attenuate X-rays, providing visualization of blood vessels, organs, and tissues during diagnostic imaging procedures.
|
|---|---|
| ln Vitro |
Iotalamic acid provides X-ray contrast activity through its iodine content. The compound is used as a contrast medium in diagnostic radiology. It displays nephrotoxicity against rat and human renal epithelial cells at levels comparable to conventional ionic contrast media.
|
| ln Vivo |
In vivo, Iotalamic acid is administered intravenously or intra-arterially for diagnostic imaging procedures. The compound provides visualization of blood vessels, organs, and tissues during X-ray or CT imaging. Its distribution is primarily in the vascular and extracellular spaces, and it is excreted renally.
|
| Enzyme Assay |
Iotalamic acid is characterized by its iodine content and X-ray attenuation properties rather than enzymatic activity. The compound's contrast efficacy is measured by its ability to attenuate X-rays, which is directly related to its iodine concentration. Quality control assays include iodine content determination and purity analysis.
|
| Cell Assay |
Iotalamic acid is used in diagnostic imaging procedures rather than cell-based assays. In vitro studies assess the compound's nephrotoxicity in renal epithelial cell lines (rat and human). Cell viability is assessed using MTT or LDH release assays. The compound's effects on renal cell function and viability are evaluated at clinically relevant concentrations.
|
| Animal Protocol |
Animal models (e.g., rats, rabbits) are used to assess the diagnostic efficacy and safety of Iotalamic acid. The compound is administered intravenously, and imaging is performed to evaluate contrast enhancement. Pharmacokinetic studies assess distribution and renal excretion. Nephrotoxicity is evaluated by renal function markers (BUN, creatinine) and histopathology.
|
| ADME/Pharmacokinetics |
Absorption, Distribution and Excretion
Kidney accumulation is rapid; in most cases, maximum contrast density is reached in the renal calyces and pelvis approximately 3 to 8 minutes after injection. Patients with impaired renal function typically require a longer time to achieve diagnostic contrast. After intravascular injection, Conjugate rapidly reaches the kidneys via the circulatory system and is excreted unchanged in the urine via glomerular filtration. The liver and small intestine are the primary alternative routes of excretion. In patients with severe renal impairment, the amount of contrast agent excreted into the small intestine via the gallbladder increases dramatically. Biological Half-Life In patients with normal renal function, the α-half-life and β-half-life of Conjugate are approximately 10 minutes and 90 minutes, respectively. Iotalamic acid has a molecular weight of 613.91 g/mol and formula C11H₉I3N2O4. The compound is water-soluble and formulated for intravenous administration. It is excreted renally and has a half-life appropriate for diagnostic imaging procedures. |
| Toxicity/Toxicokinetics |
Protein Binding
Iodotalate has a poor binding affinity to serum albumin. Iotalamic acid displays nephrotoxicity against rat and human renal epithelial cells. As an iodine-containing contrast agent, potential toxicities include nephrotoxicity, allergic reactions, and thyroid dysfunction. The compound is used in diagnostic imaging with appropriate patient monitoring for adverse reactions. |
| Additional Infomation |
Iostatin is an organic molecular entity. Iostatin is an iodine-containing organic anion used as a diagnostic contrast agent. Iostatin is a radiological contrast agent. The mechanism of action of iostatin is as an X-ray contrast agent. Iostatin is an ionic triiodobenzoate used as a contrast agent in diagnostic imaging. Like other organic iodine compounds, iostatin blocks X-rays, appearing opaque on X-ray film, thus enhancing the visibility of structures and organs during angiography, arteriography, arthrography, cholangiography, and computed tomography (CT). Iostatin is a diagnostic radiological contrast agent with properties similar to iodopantoic acid. It is primarily used in its sodium and meglumine salt forms (iostatin meglumine). See also: Iostatin meglumine (salt form). Sodium iostatin (salt form).
Drug Indications Conjugation is indicated for excretory urography, cerebral angiography, peripheral arteriography, venography, arthrography, direct cholangiography, endoscopic retrograde cholangiopancreatography, contrast-enhanced CT images of the brain, cranial CT angiography, digital subtraction angiography of veins, and digital subtraction angiography of arteries. Conjugation can also be used to enhance CT scan images to detect and evaluate lesions of the liver, pancreas, kidneys, abdominal aorta, mediastinum, abdominal cavity, and retroperitoneal space. Iotalamic acid (Iothalamic acid) is an FDA-approved radiographic contrast agent used in diagnostic imaging. It is classified as an ionic tri-iodinated benzoate compound. The compound is used for various imaging procedures including urography, angiography, and CT imaging. It is available as a diagnostic agent and is included in USP reference standards. |
| Molecular Formula |
C₁₁H₉I₃N₂O₄
|
|---|---|
| Molecular Weight |
613.91
|
| Exact Mass |
613.77
|
| CAS # |
2276-90-6
|
| Related CAS # |
Iotalamic acid-d3;928623-31-8
|
| PubChem CID |
3737
|
| Appearance |
White to off-white solid powder
|
| Density |
2.54 g/cm3
|
| Boiling Point |
520.2ºC at 760 mmHg
|
| Melting Point |
285ºC
|
| Flash Point |
268.4ºC
|
| LogP |
2.98
|
| Hydrogen Bond Donor Count |
3
|
| Hydrogen Bond Acceptor Count |
4
|
| Rotatable Bond Count |
3
|
| Heavy Atom Count |
20
|
| Complexity |
421
|
| Defined Atom Stereocenter Count |
0
|
| InChi Key |
UXIGWFXRQKWHHA-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C11H9I3N2O4/c1-3(17)16-9-7(13)4(10(18)15-2)6(12)5(8(9)14)11(19)20/h1-2H3,(H,15,18)(H,16,17)(H,19,20)
|
| Chemical Name |
3-acetamido-2,4,6-triiodo-5-(methylcarbamoyl)benzoic acid
|
| Synonyms |
Methalamic acidIotalamic acid MI 216 MI216Iothalamic acid MI-216
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ≥ 25 mg/mL (~40.72 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.08 mg/mL (3.39 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.08 mg/mL (3.39 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.08 mg/mL (3.39 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.6289 mL | 8.1445 mL | 16.2890 mL | |
| 5 mM | 0.3258 mL | 1.6289 mL | 3.2578 mL | |
| 10 mM | 0.1629 mL | 0.8145 mL | 1.6289 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
